Adar1 Capital Management, LLC Portfolio Holdings

Adar1 Capital Management, LLC

  • $500 Billion
  • Q4 2024

Adar1 Capital Management, LLC has filed its 13F form on February 13, 2025 for Q4 2024 where it was disclosed a total value porftolio of $500 Billion distributed in 214 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Roivant Sciences Ltd. with a value of $41.5B, Protagonist Therapeutics, Inc with a value of $39.4B, Ea Series Trust with a value of $35.9B, Zai Lab LTD with a value of $27.4B, and Immunovant, Inc. with a value of $19.5B.

Examining the 13F form we can see an decrease of $115B in the current position value, from $615B to 500B.

Adar1 Capital Management, LLC is based out at Austin, TX

Below you can find more details about Adar1 Capital Management, LLC portfolio as well as his latest detailed transactions.

Portfolio value $500 Billion
Healthcare: $303 Billion
ETFs: $17.1 Billion
Communication Services: $6.59 Billion
Utilities: $178 Million
Energy: $111 Million
Financial Services: $588,000

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$3.16B
$1.73 Billion 0.35% of portfolio
30,941
Q4 2024 New
$148M
$1.78 Billion 0.35% of portfolio
134,798
Q4 2024 Reduced 45.23%
Palvella Therapeutics Inc Ne
-
$1.74 Billion 0.35% of portfolio
-
Q4 2024 New
$1.52B
$1.69 Billion 0.34% of portfolio
31,509
Q4 2024 Added 142.38%
Soleno Therapeutics Inc
-
$1.66 Billion 0.33% of portfolio
-
Q4 2024 Added 268.3%
$5.62B
$1.66 Billion 0.33% of portfolio
19,661
Q4 2024 Added 3,176.83%
Kala Bio Inc
-
$1.53 Billion 0.31% of portfolio
-
Q4 2024 Reduced 28.0%
Ares Acquisition Corp Ii
-
$1.53 Billion 0.3% of portfolio
-
Q3 2024 New
$10.7B
$1.52 Billion 0.3% of portfolio
21,974
Q4 2024 Added 504.68%
$776M
$1.48 Billion 0.3% of portfolio
120,000
Q4 2024 New
Acelyrin Inc
-
$1.4 Billion 0.28% of portfolio
-
Q4 2024 Added 731.71%
$3.91B
$1.35 Billion 0.27% of portfolio
29,100
Q4 2024 Added 191.0%
$815M
$1.29 Billion 0.26% of portfolio
134,109
Q4 2024 New
$316M
$1.32 Billion 0.26% of portfolio
170,129
Q4 2024 Reduced 70.1%
$14.1B
$1.27 Billion 0.25% of portfolio
49,963
Q4 2024 Reduced 95.44%
Contineum Therapeutics Inc
-
$1.2 Billion 0.24% of portfolio
-
Q4 2024 Added 817.07%
$967M
$1.2 Billion 0.24% of portfolio
337,676
Q4 2024 Reduced 39.39%
Lexeo Therapeutics Inc
-
$1.12 Billion 0.22% of portfolio
-
Q4 2024 Added 196.51%
$802B
$1.04 Billion 0.21% of portfolio
1,350
Q4 2024 Added 17.39%
Ibio Inc
-
$1.02 Billion 0.2% of portfolio
-
Q4 2024 Reduced 12.73%
$263M
$1.01 Billion 0.2% of portfolio
131,599
Q4 2024 Reduced 65.07%
Kezar Life Sciences Inc
-
$991 Million 0.2% of portfolio
-
Q4 2024 Reduced 88.99%
-
$985 Million 0.2% of portfolio
-
Q4 2024 Reduced 79.2%
$72.2B
$969 Million 0.19% of portfolio
1,361
Q4 2024 Added 56.26%
$2.28B
$950 Million 0.19% of portfolio
38,312
Q4 2024 Reduced 12.73%
$143B
$930 Million 0.19% of portfolio
35,050
Q4 2024 Reduced 2.5%
Structure Therapeutics Inc
-
$958 Million 0.19% of portfolio
-
Q4 2024 New
$1.6B
$944 Million 0.19% of portfolio
17,424
Q4 2024 Reduced 25.72%
$2.87B
$914 Million 0.18% of portfolio
44,826
Q4 2024 Reduced 55.98%
$192M
$922 Million 0.18% of portfolio
196,248
Q4 2024 Added 251.69%
$150B
$918 Million 0.18% of portfolio
4,000
Q4 2024 New
$1.91B
$843 Million 0.17% of portfolio
19,505
Q4 2024 Added 62.54%
Agriculture & Nat Sol Acq CO
-
$843 Million 0.17% of portfolio
-
Q3 2024 New
$28.8M
$825 Million 0.16% of portfolio
801,277
Q4 2024 Added 7.78%
Keen Vision Acquisition Corp
-
$824 Million 0.16% of portfolio
-
Q4 2023 New
$107M
$813 Million 0.16% of portfolio
90,984
Q4 2024 Reduced 2.47%
$388M
$774 Million 0.15% of portfolio
56,120
Q4 2024 Added 130.88%
Neumora Therapeutics Inc.
-
$727 Million 0.15% of portfolio
-
Q4 2024 New
$31.6B
$682 Million 0.14% of portfolio
2,900
Q4 2024 New
$140M
$696 Million 0.14% of portfolio
368,330
Q4 2024 Reduced 14.1%
$163M
$719 Million 0.14% of portfolio
126,792
Q4 2024 Added 212.03%
Bioage Labs Inc
-
$712 Million 0.14% of portfolio
-
Q4 2024 New
$901M
$672 Million 0.13% of portfolio
53,023
Q4 2024 Reduced 0.17%
Cidara Therapeutics Inc
-
$670 Million 0.13% of portfolio
-
Q4 2024 New
Kiora Pharmaceuticals Inc
-
$661 Million 0.13% of portfolio
-
Q4 2024 Added 1.87%
$46.9M
$648 Million 0.13% of portfolio
122,690
Q4 2024 New
Indivior PLC
-
$672 Million 0.13% of portfolio
-
Q3 2024 Reduced 22.78%
Instil Bio Inc
-
$605 Million 0.12% of portfolio
-
Q4 2024 Added 33.75%
Solid Biosciences Inc
-
$596 Million 0.12% of portfolio
-
Q4 2024 Reduced 87.0%

Summary

  • Portfolio
  • No. of Stocks 214
  • Current Value $500 Billion
  • Prior Value $615 Billion
  • Filing
  • Period Q4 2024
  • Filing Date February 13, 2025
  • Form Type 13F-HR
  • Activity in Q4 2024
  • New Purchases 46 stocks
  • Additional Purchases 54 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 66 stocks
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email